Sign in

Private company

DYNAVAX TECHNOLOGIES CORP

In its 2025 annual report the company says: “We are a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. We are currently focused on our efforts to drive long-term shareholder value by maximizing utilization of our HEPLISAV-B® hepatitis B vaccine, expanding our own portfolio of innovative vaccine candidates leveraging our proven CpG 1018® adjuvant technology, and identifying strategic opportunities to accelerate growth through both commercial and research collaborations.”4 It is headquartered in Berkeley, United States.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersBerkeley, United States2
  • Incorporated inDE3
  • Business address2100 Powell Street, Suite 720, Emeryville, Ca 946083
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI549300T5URIXWDILX5942
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 33028042

See how the biggest companies compare on our leaderboards

We are a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. We are currently focused on our efforts to drive long-term shareholder value by maximizing utilization of our HEPLISAV-B® hepatitis B vaccine, expanding our own portfolio of innovative vaccine candidates leveraging our proven CpG 1018® adjuvant technology, and identifying strategic opportunities to accelerate growth through both commercial and research collaborations.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-1.5%Operating margin5
9.9%Net margin5
19.4%Revenue growth, 20245
4.6%Return on equity5
$60.2MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development22¢$61.5M
  • Selling, general and admin61¢$170.4M
  • Other costs5¢$14.5M
  • Income tax1¢$3.5M
  • Profit10¢$27.3M

Out of $277.2M in revenue.5

Where each dollar of operating cash went, fiscal 2024

  • Capital spending6¢$6.4M
  • Share buybacks94¢$100.0M

Out of $66.5M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.5

Financial statements

Revenue67895$277.2M in 2024+3282% since 2018
0$200.0M$400.0M$600.0M$800.0M2018: $8.2M$8.2M20182019: $35.2M$35.2M2019+330%2020: $46.6M$46.6M2020+32%2021: $439.4M$439.4M2021+844%2022: $722.7M$722.7M2022+64%2023: $232.3M$232.3M2023−68%2024: $277.2M$277.2M2024+19%
Operating income67895-$4.1M in 2024−97% since 2018
-$200.0M0$200.0M$400.0M2018: -$153.3M-$153.3M20182019: -$134.8M-$134.8M2019−12%2020: -$68.4M-$68.4M2020−49%2021: $134.5M$134.5M20212022: $283.5M$283.5M2022+111%2023: -$37.0M-$37.0M20232024: -$4.1M-$4.1M2024−89%
Net income67895$27.3M in 2024
-$200.0M0$200.0M$400.0M2018: -$158.9M-$158.9M20182019: -$152.6M-$152.6M2019−4%2020: -$75.2M-$75.2M2020−51%2021: $76.7M$76.7M20212022: $293.2M$293.2M2022+282%2023: -$6.4M-$6.4M20232024: $27.3M$27.3M2024
Fiscal year2018201920202021202220232024
Revenue$8.2M6$35.2M7$46.6M8$439.4M9$722.7M5$232.3M5$277.2M5
Research and development$75.0M6$62.3M7$28.6M8$32.2M9$46.6M5$54.9M5$61.5M5
Selling, general and admin$64.8M6$75.0M7$79.3M8$100.2M9$131.4M5$152.9M5$170.4M5
Operating expenses$305.0M9$439.2M5$269.3M5$281.4M5
Operating income-$153.3M6-$134.8M7-$68.4M8$134.5M9$283.5M5-$37.0M5-$4.1M5
Interest$9.3M6$17.0M7$19.1M8$11.2M9$6.7M9$6.8M9
Income before tax$77.5M9$294.3M5-$4.4M5$30.9M5
Income tax$06$07$08$808.0K9$1.1M5$2.0M5$3.5M5
Net income-$158.9M6-$152.6M7-$75.2M8$76.7M9$293.2M5-$6.4M5$27.3M5
Earnings per share-$2.556-$2.167-$0.758$0.629$2.325-$0.055$0.215
Earnings per share (diluted)-$2.556-$2.167-$0.788$0.579$1.975-$0.055$0.205
Shares (weighted, basic)116.3M shares9126.4M shares5128.7M shares5130.0M shares5
Shares (weighted, diluted)133.0M shares9150.8M shares5128.7M shares5133.3M shares5

Compare DYNAVAX TECHNOLOGIES CORP with another company

Corporate structure

DYNAVAX TECHNOLOGIES CORP sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of DYNAVAX TECHNOLOGIES CORP

  • Deep Track Capital, LP Filed SCHEDULE 13G/A on DYNAVAX TECHNOLOGIES CORP, latest Feb 11, 2026 (7 filings since May 19, 2023)
  • BlackRock Filed SCHEDULE 13G/A on DYNAVAX TECHNOLOGIES CORP, latest Jul 17, 2025 (8 filings since Feb 1, 2022)
  • Kynam Capital Management, LP Filed SCHEDULE 13G/A on DYNAVAX TECHNOLOGIES CORP, latest Feb 14, 2025 (2 filings since Nov 14, 2024)
  • State Street Corporation Filed SC 13G/A on DYNAVAX TECHNOLOGIES CORP, latest Oct 16, 2024 (5 filings since Oct 12, 2021)
  • Federated Hermes Filed SC 13G/A on DYNAVAX TECHNOLOGIES CORP, latest Sep 9, 2024 (4 filings since Feb 14, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on DYNAVAX TECHNOLOGIES CORP, latest Feb 13, 2024 (2 filings since Feb 9, 2023)
  • Bain Capital Life Sciences Fund, L.P. Filed SC 13D/A on DYNAVAX TECHNOLOGIES CORP, latest Aug 17, 2022
  • Chicago Capital, LLC Filed SC 13G on DYNAVAX TECHNOLOGIES CORP, latest Mar 4, 2022 (2 filings since Mar 4, 2022)
  • DYNAVAX TECHNOLOGIES CORP Berkeley, California, United States
    • DYNAVAX INDIA LLP Subsidiary · Bangalore, India

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What DYNAVAX TECHNOLOGIES CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$15.5M5 Dec 31, 2024$15.8M5 Dec 31, 2023−1.4%
Furniture and fixtures$2.5M5 Dec 31, 2024$2.5M5 Dec 31, 2023−0.7%
Leasehold improvements$36.5M5 Dec 31, 2024$37.2M5 Dec 31, 2023−1.8%
Property and equipment, before depreciation$73.2M5 Dec 31, 2024$69.1M5 Dec 31, 2023+5.8%
Accumulated depreciation$34.2M5 Dec 31, 2024$31.8M5 Dec 31, 2023+7.3%
Property and equipment, net$39.0M5 Dec 31, 2024$37.3M5 Dec 31, 2023+4.6%
Operating-lease assets (leased space)$21.6M5 Dec 31, 2024$24.3M5 Dec 31, 2023−11.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$95.9M5 Dec 31, 2024$150.3M5 Dec 31, 2023−36.2%
Marketable securities, current$618.0M5 Dec 31, 2024$592.0M5 Dec 31, 2023+4.4%
Debt securities available for sale$618.0M5 Dec 31, 2024$592.0M5 Dec 31, 2023+4.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.9M5 Dec 31, 2024$2.1M5 Dec 31, 2023−5.9%

Inventory

ItemLatestA year beforeChange
Inventory, total$70.1M5 Dec 31, 2024$53.3M5 Dec 31, 2023+31.5%
Raw materials$42.6M5 Dec 31, 2024$27.3M5 Dec 31, 2023+56.4%
Work in process$14.6M5 Dec 31, 2024$19.0M5 Dec 31, 2023−23.1%
Finished goods$12.8M5 Dec 31, 2024$7.1M5 Dec 31, 2023+81.4%

Properties, in its own words

As of December 31, 2024, the following are the material properties that we occupy:

Property Description · Location · Square Footage · Owned or Leased · Lease Expiration Date

The rest of Item 2

Corporate headquarters office · Emeryville, CA · 8,053 · Leased · July 31, 2028

Manufacturing and office space · Düsseldorf, Germany · 75,727 · Leased · December 31, 2031

Laboratory and office space · Emeryville, CA · 75,662 · Leased (*) · March 31, 2031

(*)The entire 75,662 square feet have been subleased to a third party. Both our lease and sublease with the third party will continue until March 31, 2031.

We believe that our facilities are adequate to meet our requirements for the near term.

Item 2 of the 10-K filed Feb 20, 2025.4

Leadership

Who has led DYNAVAX TECHNOLOGIES CORP, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dino Dina2006–2012
  2. Zbigniew Janowicz2009–2012
  3. Ryan Spencer2019–now

President

  1. Dino Dina2006–2010
  2. J. Tyler Martin2010–2012
  3. David F. Novack2019–now

Chief financial officer

  1. Deborah A. Smeltzer2006–2009
  2. Kelly Macdonald2021–now

Chief operating officer

  1. David F. Novack2019–now
2010201520202025
Board members and other officers (42)

Timeline

  1. Feb 10, 20268-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale61
  2. Dec 29, 20258-K Entered a material agreement; Executive or director change; Regulation FD disclosure62
  3. Nov 5, 20258-K Results of operations63
  4. Oct 16, 20258-K Executive or director change64
  5. Aug 21, 20258-K Regulation FD disclosure65
  6. Aug 7, 20258-K Results of operations66
  7. Jun 17, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed; Shareholder vote67
  8. May 13, 20258-K Executive or director change68
  9. May 6, 20258-K Results of operations69
  10. Mar 13, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares70
  11. Mar 6, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares71
  12. Feb 20, 20258-K Other events72
  13. Dec 17, 2019New chief executive Ryan Spencer becomes CEO14
  14. Mar 12, 2009New chief executive Zbigniew Janowicz becomes CEO15
  15. Feb 27, 2006New chief executive Dino Dina becomes CEO16
  16. Nov 6, 2000Founded DYNAVAX TECHNOLOGIES CORP is founded2

Calendar

When it reported results

  1. Nov 5, 2025Reported quarterly or annual results63
  2. Aug 7, 2025Reported quarterly or annual results66
  3. May 6, 2025Reported quarterly or annual results69
  4. Feb 20, 2025Reported quarterly or annual results73
  5. Jan 13, 2025Reported quarterly or annual results74
  6. Nov 7, 2024Reported quarterly or annual results75
  7. Aug 6, 2024Reported quarterly or annual results76
  8. May 8, 2024Reported quarterly or annual results77

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

366 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 47 major events, 160 insider forms, 31 large holders, 111 other. The latest 20:

  1. Feb 20, 202615-12G EDGAR
  2. Feb 13, 2026EFFECT EDGAR
  3. Feb 11, 20264 EDGAR
  4. Feb 11, 2026SCHEDULE 13G/A EDGAR
  5. Feb 10, 20264 EDGAR
  6. Feb 10, 20264 EDGAR
  7. Feb 10, 20264 EDGAR
  8. Feb 10, 20264 EDGAR
  9. Feb 10, 20264 EDGAR
  10. Feb 10, 20264 EDGAR
  11. Feb 10, 20264 EDGAR
  12. Feb 10, 20264 EDGAR
  13. Feb 10, 20264 EDGAR
  14. Feb 10, 202625-NSE EDGAR
  15. Feb 10, 20264 EDGAR
  16. Feb 10, 20264 EDGAR
  17. Feb 10, 2026S-8 POS EDGAR
  18. Feb 10, 2026S-8 POS EDGAR
  19. Feb 10, 2026S-8 POS EDGAR
  20. Feb 10, 2026S-8 POS EDGAR

The 366 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

50 open-market trades by officers, directors and large owners since October 2021: 1 buys and 49 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 15, 2026Novack David FPresident & COOSale114,000$15.64$1.8MForm 4
Dec 24, 2025Novack David FPresident & COOSale30,000$15.49$464.7KForm 4
Aug 22, 2025Myers Scott DunsethDirectorBuy3,800$10.82$41.1KForm 4
Aug 22, 2025Deep Track Capital, LP10% ownerSale970,143$10.59$10.3MForm 4
Aug 21, 2025Deep Track Capital, LP10% ownerSale1,094,994$11.03$12.1MForm 4
Mar 24, 2025Novack David FPresident & COOSale10,000$14.00$140.0KForm 4
Mar 18, 2025Novack David FPresident & COOSale14,020$13.58$190.4KForm 4
Mar 7, 2025Novack David FPresident & COOSale32,764$14.39$471.5KForm 4
May 31, 2024CANO FRANCISDirectorSale3,615$11.93$43.1KForm 4
Mar 1, 2024Burgess JustinVP Finance & CAOSale20,526$12.78$262.3KForm 4
Jan 4, 2024Janssen RobertSVP and CMOSale1,500$15.00$22.5KForm 4
Jan 2, 2024Novack David FPresident & COOSale9,000$14.45$130.1KForm 4
Dec 1, 2023Novack David FPresident & COOSale20,000$13.56$271.2KForm 4
Nov 3, 2023Novack David FPresident & COOSale20,000$15.00$300.0KForm 4
Nov 1, 2023Novack David FPresident & COOSale20,000$14.12$282.4KForm 4
Oct 10, 2023Janssen RobertSVP and CMOSale1,755$15.01$26.3KForm 4
Oct 2, 2023Novack David FPresident & COOSale40,000$14.88$595.0KForm 4
Oct 2, 2023Janssen RobertSVP and CMOSale5,015$15.03$75.4KForm 4
Sep 1, 2023Novack David FPresident & COOSale20,000$14.48$289.6KForm 4
Aug 24, 2023Janssen RobertSVP and CMOSale600$15.02$9.0KForm 4

All 50 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How DYNAVAX TECHNOLOGIES CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDYNAVAX TECHNOLOGIES CORP1
  • CIK0001029142
  • Employer ID (EIN)33-07283744
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2100 Powell Street, Suite 720, Emeryville, CA 946081
  • Phone51084851001
  • Shares outstanding117,424,968 as of Nov 3, 202512
  • Public float$800.0M as of Jun 30, 20244
  • AuditorErnst & Young LLP, San Francisco, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceDec 5, 20001
  • Filings1,689 in all: 4 (637), 8-K (378), SC 13G/A (100), 10-Q (66), 3 (53), SC 13G (47), 424B5 (31), 144 (29)1
    All 61 form types

    CT ORDER (26), DEFA14A (25), DEF 14A (24), 10-K (22), S-8 (20), S-8 POS (20), 4/A (19), UPLOAD (18), CORRESP (17), EFFECT (15), S-3 (13), DFAN14A (11), SC 13D/A (10), 424B3 (7), PRE 14A (7), 424B4 (5), 8-K/A (5), S-1/A (5), S-3/A (5), S-3ASR (5), SC 13D (5), ARS (4), SC 14D9/A (4), SCHEDULE 13G/A (4), POS AM (3), REGDEX (3), REGDEX/A (3), SC TO-T/A (3), 10-K/A (2), 3/A (2), 424B2 (2), 424B7 (2), 5 (2), 8-A12B (2), D (2), DEFC14A (2), POSASR (2), PREC14A (2), PRER14A (2), RW (2), S-1 (2), SC14D9C (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 8-A12G (1), DEFR14A (1), FWP (1), PRRN14A (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Feb 20, 2025
    Quarterly report (10-Q) Nov 5, 2025
    Proxy statement (DEF 14A) Apr 11, 2024
    Latest 8-K (8-K) Feb 10, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par valueDVAXNasdaq Global Select Market
Preferred Share Purchase RightsNasdaq Global Select Market

From the cover page of the 10-K filed Feb 20, 2025 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks DYNAVAX TECHNOLOGIES CORP names in Item 1A of its 10-K filed Feb 20, 2025: 49 risks under these headings, as written.4

  • Risks Related to our Business and Capital Requirements
  • HEPLISAV-B has been approved in the United States, the European Union and the United Kingdom and launched in the United States and Germany, and there is significant competition in these marketplaces. Since this is our first marketed product, the timing of uptake and distribution efforts are unpredictable and there is a risk that we may not achieve and sustain commercial success for HEPLISAV-B.
  • Our financial results may vary significantly from quarter to quarter or may fall below the expectations of investors or securities analysts, each of which may adversely affect our stock price.
  • We have incurred annual net losses in most years since our inception and could continue to incur significant losses if we do not successfully commercialize HEPLISAV-B, launch new products and/or significant sales of our CpG 1018 adjuvant do not resume.
  • Many of our competitors have greater financial resources and expertise than we do. If we are unable to successfully compete with existing or potential competitors as a result of these disadvantages, we may be unable to generate sufficient, or any, revenues and our business will be harmed.
  • As we continue to focus on the commercialization of our HEPLISAV-B vaccine and our CpG 1018 adjuvant, we may encounter difficulties in managing our commercial growth and expanding our operations successfully.
  • If HEPLISAV-B or any products we develop are not accepted by the market or if regulatory authorities limit our labeling indications, require labeling content that diminishes market uptake of HEPLISAV-B or any other products we develop, or limit our marketing claims, we may be unable to generate significant future revenues, if any.
  • As we continue to grow as a commercial organization and enter into supply agreements with customers, those supply agreements will have obligations to deliver product that we are in part reliant upon third parties to manufacture on our behalf.
  • We face uncertainty regarding coverage, pricing and reimbursement and the practices of third-party payors, which may make it difficult or impossible to sell certain of our products or product candidates on commercially reasonable terms.
  • We are subject to ongoing FDA, EU and comparable foreign post-marketing obligations concerning HEPLISAV-B, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated regulatory issues with HEPLISAV-B.
  • HEPLISAV-B and all of our clinical programs rely on oligonucleotide TLR agonists. In the event of serious adverse events relating to TLR agonists, we may be required to reduce the scope of, or discontinue, our operations, or reevaluate the viability of strategic alternatives.
  • HEPLISAV-B is subject to regulatory obligations and continued regulatory review, and if we receive regulatory approval for our other product candidates, we will be subject to ongoing FDA and foreign regulatory obligations and continued regulatory review for such products.
The other 38 risks
  • Regulatory authorities may require more clinical trials for our product candidates than we currently expect or are conducting before granting regulatory approval, if regulatory approval is granted at all. Our clinical trials may be extended which may lead to substantial delays in the regulatory approval process for our product candidates and may impair our ability to generate revenues.
  • Clinical trials for our commercial product and product candidates are expensive and time consuming, may take longer than we expect or may not be completed at all, and have uncertain outcomes.
  • A key part of our business strategy for products in development is to establish collaborative relationships to help fund or manage development and commercialization of our product candidates and research programs. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to continue to develop and commercialize those products and programs, if at all.
  • Until we are able to generate significant revenues or achieve profitability through product sales on a consistent basis, we may require substantial additional capital to finance our operations.
  • As we plan for the broader commercialization of our HEPLISAV-B vaccine and for the requisite capacity to manufacture our CpG 1018 adjuvant, our financial commitments for manufacturing and supply capacity might outpace actual demand for our products.
  • We may develop, seek regulatory approval for and market HEPLISAV-B or any other product candidates outside of the U.S., the European Union and the United Kingdom, requiring a significant additional commitment of resources. Failure to successfully manage our international operations could result in significant unanticipated costs and delays in regulatory approval or commercialization of our products or product candidates.
  • We rely on CROs and clinical sites and investigators for our clinical trials. If these third parties do not fulfill their contractual obligations or meet expected deadlines, our planned clinical trials may be delayed and we may fail to obtain the regulatory approvals necessary to commercialize our product candidates.
  • As a biopharmaceutical company, we engage CROs to conduct clinical studies, and failure by us or our CROs to conduct a clinical study in accordance with GCP standards and other applicable regulatory requirements could result in disqualification of the applicable clinical trial from consideration in support of approval of a potential product.
  • Our ability to use our net operating loss carryforwards and other tax attributes may be limited.
  • Tax law changes could adversely affect our business and financial condition.
  • If we fail to comply with the extensive requirements applicable to biopharmaceutical manufacturers and marketers under the healthcare fraud and abuse, anticorruption, privacy, transparency and other laws of the jurisdictions in which we conduct our business, we may be subject to significant liability.
  • We have applied for, and in some cases have received, grants that, if and when received, may involve pricing or other restrictions.
  • Enacted or future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may have an adverse effect on our operations and business.
  • In connection with our work with the U.S. Department of Defense ("DoD"), we have become a defense contractor, and are therefore subject to additional administrative burdens and control requirements in connection with the maintenance of that relationship.
  • We face product liability exposure, which, if not covered by insurance, could result in significant financial liability.
  • Risks Related to our Intellectual Property
  • If third parties assert that we have infringed their patents or other proprietary rights or challenge our patents or other proprietary rights, we may become involved in disputes and litigation that would be costly, time consuming and have a negative impact on the commercialization of our current products and delay or prevent development or commercialization of our product candidates.
  • If the combination of patents, trade secrets and contractual provisions that we rely on to protect our intellectual property is inadequate, the value of our products or product candidates may decrease, and we may be unable to realize any commercial benefit from the development of our products or product candidates.
  • We have in the past, and may in the future, rely on licenses to intellectual property from third parties. Impairment of these licenses or our inability to obtain or maintain them could severely harm our business.
  • We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees’ or consultants’ former employers or their clients. These claims may be costly to defend and if
  • we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • Risks Related to our Common Stock
  • Our stock price is subject to volatility, and your investment may suffer a decline in value.
  • Future sales of our common stock or the perception that such sales may occur in the public market could cause our stock price to fall.
  • There can be no assurance with respect to the number of shares of our common stock repurchased under the share repurchase program or that our share repurchase program will provide the benefits anticipated.
  • The anti-takeover provisions of our certificate of incorporation, our bylaws, Delaware law and our stockholder rights plan may prevent or frustrate a change in control, even if an acquisition would be beneficial to our stockholders, which could affect our stock price adversely and prevent attempts by our stockholders to replace or remove our current management.
  • Risks Related to Our Outstanding Convertible Notes
  • Servicing our Convertible Notes requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.
  • We may not have the ability to generate or raise the funds necessary to settle conversions of the Convertible Notes in cash or to repurchase the notes for cash upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Convertible Notes.
  • The conditional conversion feature of the Convertible Notes may adversely affect our financial condition and operating results.
  • Conversion of the Convertible Notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.
  • Certain provisions in the indenture governing the Convertible Notes may delay or prevent an otherwise beneficial takeover attempt of us.
  • The Capped Calls may affect the value of the Convertible Notes and our common stock.
  • We are subject to counterparty risk with respect to the capped call transactions.
  • General Risk Factors
  • The loss of key personnel could delay or prevent achieving our objectives. In addition, our continued growth to support commercialization may result in difficulties in managing our growth and expanding our operations successfully.
  • Our business operations are vulnerable to interruptions by natural disasters, health epidemics and other catastrophic events beyond our control, the occurrence of which could materially harm our manufacturing, distribution, sales, business operations and financial results.
  • If our information technology systems or those of third parties upon which we rely, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.
  • Adverse developments affecting the financial services industry may have adverse consequences on our business, financial condition and stock price.

Legal proceedings

From time to time in the ordinary course of business, we receive claims or allegations regarding various matters, including employment, vendor and other similar situations in the conduct of our operations. We are not currently aware of any material legal proceedings involving our Company.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
    SEC EDGAROther events
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85